Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

PRP knee injections: new study looks at blood protein changes in osteoarthritis patients

NCT ID NCT06451120

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This study tests whether platelet-rich plasma (PRP) injections into the knee can change certain proteins in the blood of people with knee osteoarthritis. About 60 participants aged 18-70 will receive either PRP or a saltwater placebo, and researchers will compare protein levels to understand how PRP might work. The goal is to learn more about the body's response to PRP, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Grade 1-3 KL score will be recruited; 2. Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee; 3. Have symptomatic complaints from osteoarthritis pain in no other joint affecting the hips, ankles or unaffected knee; 4. Will be able to attend and perform physical therapy. 5. English-speaking Exclusion Criteria 1\. Patients will be excluded if: 1. Received injection therapy for knee osteoarthritis in the past 6 months 2. Have signs of concomitant osteoarthritis of 1 or more other major joints of the lower extremities that impair their daily activity level 3. History of septic arthritis 4. Have underwent a previous knee surgery specifically for osteoarthritis or osteochondral defects less than 1 year before randomization (i.e. autograft or allograft surgery 5. High tibial osteotomy, partial knee replacement, patellar resurfacing), total knee replacement or existing surgical hardware in the knee 6. Patient with platelet disorders, bleeding disorder 7. Patient with rheumatologic disease, automimmune disorder, immunocompromised status, active history of cancer 8. Patient taking Chemotherapy, need for regular prednisone or antiinflammatory used 9. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 10. Uncontrolled illness, physical disability, or other contraindication to aerobic exercise training including, but not limited to: i. Acute myocardial Infarction (within 5 days of any planned study procedure); ii. Unstable angina; iii. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise; iv. Recurrent syncope; v. Active endocarditis; vi. Acute myocarditis or pericarditis; vii. Symptomatic severe aortic stenosis; viii. Uncontrolled heart failure; ix. Acute (within 3 months) pulmonary embolus or pulmonary infarction; x. Thrombosis of lower extremities; xi. Suspected dissecting aneurysm; xii. Uncontrolled asthma; xiii. Pulmonary edema; xiv. Room air desaturation at rest ≤85%; xv. Respiratory failure; xvi. Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (ie infection, renal failure, thyrotoxicosis); and xvii. Mental impairment leading to inability to cooperate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Articular cartilage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.